Longeveron (LGVN) Stock Forecast, Price Target & Predictions
LGVN Stock Forecast
Longeveron stock forecast is as follows: an average price target of $10.00 (represents a 362.96% upside from LGVN’s last price of $2.16) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LGVN Price Target
LGVN Analyst Ratings
Longeveron Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 29, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $3.44 | 190.70% | 362.96% |
Longeveron Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $10.00 |
Last Closing Price | $2.16 | $2.16 | $2.16 |
Upside/Downside | -100.00% | -100.00% | 362.96% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 27, 2024 | Maxim Group | Buy | Buy | Hold |
Jul 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Longeveron Financial Forecast
Longeveron Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $150.00K | $217.00K | $279.00K | $121.00K | $265.00K | $466.00K | $370.00K | $209.00K |
Avg Forecast | $1.23M | $1.18M | $1.09M | $1.05M | $609.50K | $594.50K | $564.00K | $549.00K | $408.00K | $395.50K | $500.00K | $60.00K | $210.00K | $400.00K | $400.00K | $300.00K | $400.00K | $200.00K | $200.00K | $250.00K | $265.00K |
High Forecast | $1.23M | $1.18M | $1.09M | $1.05M | $609.50K | $594.50K | $564.00K | $549.00K | $408.00K | $430.40K | $500.00K | $60.00K | $290.00K | $400.00K | $400.00K | $300.00K | $400.00K | $200.00K | $200.00K | $250.00K | $265.00K |
Low Forecast | $1.23M | $1.18M | $1.09M | $1.05M | $609.50K | $594.50K | $564.00K | $549.00K | $408.00K | $348.97K | $500.00K | $60.00K | $130.00K | $400.00K | $400.00K | $300.00K | $400.00K | $200.00K | $200.00K | $250.00K | $265.00K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.54% | 0.93% | 0.30% | 1.32% | 2.33% | 1.48% | 0.79% |
Longeveron EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.16M | $-5.71M | $-4.72M | $-4.56M | $-5.00M | $-4.00M | $-3.21M | $-8.46M |
Avg Forecast | $-960.77K | $-925.59K | $-854.45K | $-818.49K | $-476.48K | $-464.75K | $-440.91K | $-429.18K | $-318.95K | $-309.18K | $-390.88K | $-46.91K | $-164.17K | $-312.70K | $-312.70K | $-234.53K | $-312.70K | $-156.35K | $-156.35K | $-4.08M | $-207.16K |
High Forecast | $-960.77K | $-925.59K | $-854.45K | $-818.49K | $-476.48K | $-464.75K | $-440.91K | $-429.18K | $-318.95K | $-272.81K | $-390.88K | $-46.91K | $-101.63K | $-312.70K | $-312.70K | $-234.53K | $-312.70K | $-156.35K | $-156.35K | $-3.26M | $-207.16K |
Low Forecast | $-960.77K | $-925.59K | $-854.45K | $-818.49K | $-476.48K | $-464.75K | $-440.91K | $-429.18K | $-318.95K | $-336.46K | $-390.88K | $-46.91K | $-226.71K | $-312.70K | $-312.70K | $-234.53K | $-312.70K | $-156.35K | $-156.35K | $-4.89M | $-207.16K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.50% | 18.27% | 20.11% | 14.57% | 32.01% | 25.56% | 0.79% | 40.85% |
Longeveron Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.90M | $-5.63M | $-4.58M | $-3.77M | $-5.30M | $-7.03M | $-3.63M | $-8.92M |
Avg Forecast | - | - | - | - | $-1.82M | $-1.89M | $-2.34M | $-2.47M | $-2.31M | $-2.54M | $-7.29M | $-13.05M | $-13.89M | $-14.65M | $-16.06M | $-13.89M | $-13.02M | $-14.32M | $-14.76M | $-4.31M | $-16.27M |
High Forecast | - | - | - | - | $-1.82M | $-1.89M | $-2.34M | $-2.47M | $-2.31M | $-2.44M | $-7.29M | $-13.05M | $-12.57M | $-14.65M | $-16.06M | $-13.89M | $-13.02M | $-14.32M | $-14.76M | $-3.45M | $-16.27M |
Low Forecast | - | - | - | - | $-1.82M | $-1.89M | $-2.34M | $-2.47M | $-2.31M | $-2.63M | $-7.29M | $-13.05M | $-15.21M | $-14.65M | $-16.06M | $-13.89M | $-13.02M | $-14.32M | $-14.76M | $-5.17M | $-16.27M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.40% | 0.35% | 0.33% | 0.29% | 0.37% | 0.48% | 0.84% | 0.55% |
Longeveron SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.37M | $3.52M | $2.01M | $1.92M | $2.32M | $2.66M | $2.27M | $5.39M |
Avg Forecast | $8.39M | $8.08M | $7.46M | $7.15M | $4.16M | $4.06M | $3.85M | $3.75M | $2.78M | $2.70M | $3.41M | $409.46K | $1.43M | $2.73M | $2.73M | $2.05M | $2.73M | $1.36M | $1.36M | $1.71M | $1.81M |
High Forecast | $8.39M | $8.08M | $7.46M | $7.15M | $4.16M | $4.06M | $3.85M | $3.75M | $2.78M | $2.94M | $3.41M | $409.46K | $1.98M | $2.73M | $2.73M | $2.05M | $2.73M | $1.36M | $1.36M | $1.71M | $1.81M |
Low Forecast | $8.39M | $8.08M | $7.46M | $7.15M | $4.16M | $4.06M | $3.85M | $3.75M | $2.78M | $2.38M | $3.41M | $409.46K | $887.16K | $2.73M | $2.73M | $2.05M | $2.73M | $1.36M | $1.36M | $1.71M | $1.81M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.24% | 1.29% | 0.98% | 0.70% | 1.70% | 1.95% | 1.33% | 2.98% |
Longeveron EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.27 | $-0.22 | $-0.18 | $-0.25 | $-0.34 | $-0.17 | $-0.45 |
Avg Forecast | - | - | - | - | $-0.28 | $-0.29 | $-0.36 | $-0.38 | $-0.35 | $-0.39 | $-1.12 | $-2.00 | $-2.13 | $-2.25 | $-2.47 | $-2.13 | $-2.00 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
High Forecast | - | - | - | - | $-0.28 | $-0.29 | $-0.36 | $-0.38 | $-0.35 | $-0.38 | $-1.12 | $-2.00 | $-1.93 | $-2.25 | $-2.47 | $-2.13 | $-2.00 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Low Forecast | - | - | - | - | $-0.28 | $-0.29 | $-0.36 | $-0.38 | $-0.35 | $-0.40 | $-1.12 | $-2.00 | $-2.34 | $-2.25 | $-2.47 | $-2.13 | $-2.00 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.11% | 0.10% | 0.09% | 0.11% | 0.15% | 0.08% | 0.18% |
Longeveron Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
KPRX | Kiora Pharmaceuticals | $3.68 | $120.00 | 3160.87% | Buy |
BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
LGVN | Longeveron | $2.16 | $10.00 | 362.96% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
LGVN Forecast FAQ
Is Longeveron a good buy?
Yes, according to 2 Wall Street analysts, Longeveron (LGVN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of LGVN's total ratings.
What is LGVN's price target?
Longeveron (LGVN) average price target is $10 with a range of $10 to $10, implying a 362.96% from its last price of $2.16. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Longeveron stock go up soon?
According to Wall Street analysts' prediction for LGVN stock, the company can go up by 362.96% (from the last price of $2.16 to the average price target of $10), up by 362.96% based on the highest stock price target, and up by 362.96% based on the lowest stock price target.
Can Longeveron stock reach $3?
LGVN's average twelve months analyst stock price target of $10 supports the claim that Longeveron can reach $3 in the near future.
What are Longeveron's analysts' financial forecasts?
Longeveron's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.32M (high $2.32M, low $2.32M), average EBITDA is $-1.811M (high $-1.811M, low $-1.811M), average net income is $-8.528M (high $-8.528M, low $-8.528M), average SG&A $15.81M (high $15.81M, low $15.81M), and average EPS is $-1.31 (high $-1.31, low $-1.31). LGVN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.55M (high $4.55M, low $4.55M), average EBITDA is $-3.559M (high $-3.559M, low $-3.559M), average net income is $0 (high $0, low $0), average SG&A $31.07M (high $31.07M, low $31.07M), and average EPS is $0 (high $0, low $0).
Did the LGVN's actual financial results beat the analysts' financial forecasts?
Based on Longeveron's last annual report (Dec 2023), the company's revenue was $709K, which missed the average analysts forecast of $1.31M by -45.88%. Apple's EBITDA was $-21.029M, beating the average prediction of $-1.024M by 1953.43%. The company's net income was $-22.211M, missing the average estimation of $-58.48M by -62.02%. Apple's SG&A was $12.18M, beating the average forecast of $8.94M by 36.29%. Lastly, the company's EPS was $-0.001, missing the average prediction of $-8.983 by -99.99%. In terms of the last quarterly report (Sep 2023), Longeveron's revenue was $150K, missing the average analysts' forecast of $400K by -62.50%. The company's EBITDA was $-5.161M, beating the average prediction of $-313K by 1550.46%. Longeveron's net income was $-5.904M, missing the average estimation of $-14.647M by -59.69%. The company's SG&A was $3.37M, beating the average forecast of $2.73M by 23.53%. Lastly, the company's EPS was $-0.28, missing the average prediction of $-2.25 by -87.56%